Pharma & Biotech Mergers & Acquisitions News
Pharmaceutical
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Pharmaceutical
Immedica Pharma, a Swedish company specializing in rare diseases, has announced its acquisition of Marinus Pharmaceuticals in a deal valued at $151 million. The agreement, finalized through a cash tender offer, marks a significant expansion of Immedica’s presence in the US market. 6 January 2025
Pharmaceutical
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Pharmaceutical
Regeneron Pharmaceuticals has acquired UK-based biotech Oxular, enhancing its gene therapy development program with the firm’s specialized ocular delivery tech. 3 January 2025
Pharmaceutical
Denmark-based diabetes and obesity giant Novo Nordisk says it plans to invest 8.5 billion Danish kroner ($1.2 billion) to establish a completely new production facility in Odense, Denmark. 16 December 2024
Pharmaceutical
The pharmaceutical and life sciences industry is gearing up for what analysts at PwC predict will be a highly active year for mergers and acquisitions in 2025, following a mixed performance in 2024. 13 December 2024
Pharmaceutical
Canada-headquartered Bausch + Lomb Corporation, a leading global eye health company, on Thursday confirmed reports that it is exploring a potential sale, acting in response to a request from the Canadian Investment Regulatory Organization (CIRO). 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Pharmaceutical
GE Healthcare has announced plans to acquire from Sumitomo Chemical the half of Nihon Medi-Physics (NMP) that it doesn’t own. 5 December 2024
Pharmaceutical
Germany’s Evotec has said its chief operating officer Craig Johnstone will leave the business at the end of the year. 29 November 2024
Pharmaceutical
Munich, Germany headquartered contract development and manufacturing organization (CDMO) Adragos Pharma has acquired Baccinex, a Swiss-based expert in aseptic fill-finish manufacturing. 28 November 2024
Pharmaceutical
The board of Spanish plasma-based medicines producer Grifols has announced the termination of discussions with Brookfield Capital Partners (UK) regarding a potential acquisition of Grifols shares. 28 November 2024
Pharmaceutical
Swiss pharma giant Novartis today announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management event for investors and analysts in London. 21 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Pharmaceutical
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Pharmaceutical
Pharmaceutical M&A came back with a bang during October, after a quiet September. 5 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Pharmaceutical
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
Pharmaceutical
French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). 21 October 2024
Pharmaceutical
A recent survey of top life sciences organizations found that compliance issues and increased industry consolidation (via mergers and acquisitions) are the top challenges faced by companies in today's market. The survey, conducted by Sparta Systems, pointed to the need to achieve compliance with worldwide regulatory standards as a major issue for organizations trying to maintain their competitive edge in global life sciences industries. 11 February 2010
Pharmaceutical
California, USA-based BioMarin Pharmaceutical has entered into a stock purchase agreement to acquire LEAD Therapeutics, a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of patients with rare, genetically defined cancers. 5 February 2010
Pharmaceutical
French drug major Sanofi-Aventis has entered into a deal with Minsheng Pharmaceutical to form a new consumer health care joint venture. Subject to certain conditions precedent and to regulatory approvals, Sanofi-Aventis will take a majority equity stake in the new company. 1 February 2010
Pharmaceutical
US health care major Abbott Laboratories reported that its fourth-quarter profit was virtually flat with that of the year-earlier quarter, due largely to various accounting charges but, nevertheless, recorded strong sales growth. Abbott dipped 1.1%, to $53.90 at 4 p.m. in New York Stock Exchange composite trading following the announcement. 28 January 2010
Pharmaceutical
The European Commission revealed on Friday that it has extended its antitrust investigation of US health care major Abbott Laboratories' planned acquisition of the pharmaceutical business of Belgian company Solvay SA by 10 working days to February 11. 25 January 2010
Pharmaceutical
French drugmaker Ipsen and California, USA-based Inspiration Biopharmaceuticals have entered into a partnership to create a world leading hemophilia franchise in order to develop drugs to treat hemophilia that could generate sales of over $1 billion by 2020 and could lead to Ipsen's eventual acquisition of the US firm. 21 January 2010
Pharmaceutical
Responding formally to Swiss drug major Novartis' offer to buy the global eye-care leader (The Pharma Letter June 4), the Independent Director Committee of Alcon lambasted the deal proposed to independent shareholders, which was significantly lower than that made for a majority stake to be acquired from food giant Nestle, using terms such as 'grossly inadequate, offensive and disrespectful' to describe the terms. 21 January 2010
Pharmaceutical
Indian drug major Ranbaxy Laboratories, which is 64% owned by Japan's Daiichi Sankyo, has today signed an of agreements with Biovel Lifesciences based in Bangalore, India, to acquire the latter's product rights and a manufacturing facility. 19 January 2010
Pharmaceutical
its large production site in Shanghai. Financial terms of the deal were not disclosed. 15 January 2010
Pharmaceutical
Following the announcement that Swiss drug major Novartis had entered a deal with food giant Nestle to gain control of leading eye-care company Alcon (The Pharma Letter January 4), and while the latter's Independent Committee of Directors is still fuming that other shareholders had been offered an unfair deal, US minority investors in the company have taken things into their own hands, launching a law suit against both Novartis and Alcon. 12 January 2010
Pharmaceutical
Japanese drug major Daiichi Sankyo's US unit, Luitpold Pharmaceuticals, has acquired PharmaForce, a privately-held, fully integrated specialty injectable pharmaceutical company based in Ohio. Financial terms of the deal were not disclosed. 6 January 2010
Pharmaceutical
UK-based Proximagen Neuroscience has reached agreement with Britain's Minster Pharmaceuticals to acquire the latter for 6 pence a share, or a total of about 4.3 million ($6.9 million), a premium of some 45.5% on its closing price December 31, 2009, the last trading day prior to the announcement. 6 January 2010
Pharmaceutical
German drugmaker Merz Pharma has entered into an agreement to acquire all of the outstanding shares of USA-based, privately-held BioForm Medical for $5.45 per share in cash pursuant to a cash tender offer followed by a second-step merger. The transaction has a total equity value of approximately $253 million based on BioForm Medical's outstanding shares of common stock. 5 January 2010
Pharmaceutical
USA-based Anika Therapeutics announced on December 31 that it has acquired Fidia Advanced Biopolymers, a wholly-owned subsidiary of privately-held Italian drugmaker Fidia Farmaceutici SpA. 5 January 2010
Pharmaceutical
India's largest drugmaker Ranbaxy Laboratories, which is majority (64%) owned by Japanese drug major Daiichi Sankyo, is to sell its China-based joint-venture subsidiary Ranbaxy Guangzhou China - which was set up around 16 years ago - to partner HNG Chembio Pharmacy (part of the large Chinese state-owned Hunan Nonferrous Metals Holding. Financial terms of the divestment of the JV, in which Ranbaxy held an 83% stake, were not revealed. 4 January 2010
Pharmaceutical
Korean health care and medical equipment maker Arigene has informed USA-based Trimeris that it intends to terminate the tender offer made last October for all of Trimeris' outstanding shares of common stock because it was unable to secure sufficient financing for the tender offer, valued at some $81 million, or $3.60 a share, which expired on December 28, 2009. 4 January 2010
Pharmaceutical
Anglo-Swedish drug major AstraZeneca revealed yesterday afternoon that it is to acquire Novexel, a French speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial drug resistance, which was spun out of what became Sanofi-Aventis in 2004. It will also collaborate with Forest Laboratories on the future co-development and commercialization of two late-stage antibiotic development programs. 24 December 2009
Pharmaceutical
Novartis will gain exclusive worldwide rights to relaxin, a recombinant version of a naturally occurring human peptide, through the acquisition of the privately held US biopharmaceutical company Corthera. Relaxin is currently in Phase III clinical trials as a potential treatment option for patients with acute decompensated heart failure (ADHF). 23 December 2009
Pharmaceutical
In a move that will take it up to fifth place in global consumer health care ' and confirming its aims to expand in niche markets rather than through mega buys/mergers, French drug major Sanofi-Aventis says it has entered into a deal to acquire the US firm Chattem in a deal valuing the latter at some $1.9 billion. 22 December 2009
Pharmaceutical
Japanese drug major Eisai has said it will initiate procedures to acquire New Jersey, USA-based AkaRx under a deal valuing the business at $255 million and making it a wholly-owned subsidiary of its US affiliate. Eisai obtained the right to buy AkaRx after it acquired MGI Pharma in January last year for $3.9 billion. 21 December 2009
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze